Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) -- The ex-dividend date for
) is tomorrow, March 27, 2013. Owners of shares as of market close today will be eligible for a dividend of 48 cents per share. At a price of $49.48 as of 9:30 a.m. ET, the dividend yield is 6.7%.
The average volume for AstraZeneca has been 1.8 million shares per day over the past 30 days. AstraZeneca has a market cap of $61.35 billion and is part of the health care sector and drugs industry. Shares are up 5% year to date as of the close of trading on Monday.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. The company has a P/E ratio of 6.7, below the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates AstraZeneca as a
. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full
It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE